div style=”text-align: justify;”Goldman Sachs is upgrading span style=”font-weight: bold;”Biogen-Idec (NASDAQ:BIIB)/span to Buy from Neutral and adding the stock to their Conviction Buy list with a $61 tgt (up from $57).br /br /According to the firm this is based on potential upside revision to earnings and attractive valuation. They believe the threat of generics and competition should be manageable, leading to their 2009/2010 EPS (incl. ESO) of $4.14 amp; $4.55 vs. consensus of $3.97 and $4.23, resp. BIIB’s pipeline is underestimated and should gain visibility in 2009/2010. The product profile and manufacturing capacity might be attractive for potential pharma acquirers. The intrinsic value of $46 implies a pipeline value of $3 which the firm views as attractive.br /br /span style=”font-weight: bold;”Catalyst/spanbr /span style=”font-weight: bold;”/spanbr /1) Safety data from over 10,000 patients on Tysabri therapy by yearend.br /br /2) In 2009, MLCO expects Phase 3 data on Rituxan in lupus nephritis (1Q, $1bn potential), Phase 2 data on CDP323 for multiple sclerosis (MS), BIIB14 for Parkinson’s disease, and HSP90 inhibitor for cancer, as well as Phase 1/2 results on long acting Avonex for MS and long acting Factor IX for hemophilia B. Combined potential of the Phase 1amp;2 programs exceeds $3 bn.br /br /3) Detailed data on two competing agents in MS in 4/09.br /br /span style=”color: rgb(255, 0, 0);”Notablecalls:/span Could do 3-4% to the upside.br //div

Last 5 posts by Notable Calls

• Petroquest Energy (NYSE:PQ): Compelling Valuation with Near-Term Catalysts; Upgrading to Overweight - J.P. Morgan - October 29th, 2009
• 15% correction coming in SP500? - October 21st, 2009
• Boeing (NYSE:BA): Downgraded to Underweight at Morgan Stanley, target to $43 - October 20th, 2009
• Par Pharmaceuticals (NYSE:PRX): Upgraded to Overweight at Barclays; target raised to $30 - October 15th, 2009
• Wyndham Worldwide (NYSE:WYN): Upgraded to Buy at Goldman Sachs; $26 target established - October 7th, 2009